Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M710518200 on March 10, 2008

J. Biol. Chem., Vol. 283, Issue 18, 12546-12554, May 2, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/18/12546    most recent
M710518200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koga, T.
Right arrow Articles by Li, J.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koga, T.
Right arrow Articles by Li, J.-D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Tumor Suppressor Cylindromatosis Acts as a Negative Regulator for Streptococcus pneumoniae-induced NFAT Signaling*

Tomoaki Koga{ddagger}, Jae Hyang Lim{ddagger}, Hirofumi Jono{ddagger}, Un Hwan Ha{ddagger}, Haidong Xu{ddagger}, Hajime Ishinaga{ddagger}, Saori Morino§, Xiangbin Xu{ddagger}, Chen Yan1, Hirofumi Kai§, and Jian-Dong Li{ddagger}2

From the {ddagger}Department of Microbiology and Immunology and Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York 14642 and the §Department of Molecular Medicine, Kumamoto University, Kumamoto 862-0973, Japan

Received for publication, December 26, 2007 , and in revised form, February 20, 2008.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Gram-positive bacterium Streptococcus pneumoniae is an important human pathogen that colonizes the upper respiratory tract and is also the major cause of morbidity and mortality worldwide. S. pneumoniae causes invasive diseases such as pneumonia, meningitis, and otitis media. Despite the importance of pneumococcal diseases, little is known about the molecular mechanisms by which S. pneumoniae-induced inflammation is regulated, especially the negative regulatory mechanisms. Here we show that S. pneumoniae activates nuclear factor of activated T cells (NFAT) signaling pathway and the subsequent up-regulation of inflammatory mediators via a key pneumococcal virulence factor, pneumolysin. We also demonstrate that S. pneumoniae activates NFAT transcription factor independently of Toll-like receptors 2 and 4. Moreover, S. pneumoniae induces NFAT activation via both Ca2+-calcineurin and transforming growth factor-β-activated kinase 1 (TAK1)-mitogen-activated protein kinase kinase (MKK) 3/6-p38{alpha}/β-dependent signaling pathways. Interestingly, we found for the first time that tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for S. pneumoniae-induced NFAT signaling pathway via a deubiquitination-dependent mechanism. Finally, we showed that CYLD interacts with and deubiquitinates TAK1 to negatively regulate the activation of the downstream MKK3/6-p38{alpha}/β pathway. Our studies thus bring new insights into the molecular pathogenesis of S. pneumoniae infections through the NFAT-dependent mechanism and further identify CYLD as a negative regulator for NFAT signaling, thereby opening up new therapeutic targets for these diseases.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In the host innate immune system, epithelial cells are situated at host/environment boundaries and thus act as the first line of host defense against various pathogens (1, 2). The principal challenge for the host is to efficiently detect the invading pathogen and mount a rapid defensive response. Epithelial cells are thus responsible for the initiation of local immune responses that may be crucial for prevention of invasive infection. Among the various invading pathogens, Gram-positive bacterium Streptococcus pneumoniae is known as an important human pathogen that colonizes the upper respiratory tract and is a major cause of morbidity and mortality worldwide (3). S. pneumoniae causes invasive diseases such as pneumonia, meningitis, and bacteremia, as well as otitis media and sinusitis. Among a variety of virulence factors that have been identified, pneumolysin (PLY),3 a 53-kDa protein produced by virtually all clinical isolates of S. pneumoniae, plays an important role in mortality associated with S. pneumoniae infections and is released during respiratory infections in human by bacterial autolysis (4-6). PLY is classically defined as a cytolytic toxin (7). At low sublytic concentrations, however, PLY also serves as a potent inducer of host defense response. Despite the importance of pneumococcal diseases, little is known about the molecular mechanisms by which S. pneumoniae PLY-induced inflammation is regulated, especially the negative regulatory mechanisms. Moreover, because of inappropriate antibiotic use in the clinic, antibiotic-resistant strains of S. pneumoniae have increased over the past decade (8, 9). Therefore, development of alternative therapeutic strategies targeting host response is urgently needed for the treatment of S. pneumoniae infections based on full understanding of the molecular pathogenesis of S. pneumoniae infections.

Nuclear factor of activated T cells (NFAT) has been identified in T cells as a rapidly inducible transcription factor that binds to the distal promoter of human interleukin-2 (IL-2) and also regulates the expression of other inflammatory cytokines and cell surface receptors in immune cells (10). However, subsequent studies have revealed that NFAT is also functionally expressed in many other cell types and tissues (11-13). NFAT is present in the cytoplasm in an inactive status and is highly phosphorylated. To translocate NFAT into the nucleus, NFAT needs to be dephosphorylated. The phosphorylation status of NFAT is regulated by various kinases and phosphatases, including p38 MAPK and calcineurin, a Ca2+/calmodulin-dependent serine-threonine phosphatase (10, 14). The role of NFAT and how its function is regulated in bacterial infections, however, remain largely unknown.

Recently, the tumor suppressor cylindromatosis (CYLD), known as a deubiquitinase, loss of which causes a benign human syndrome called cylindromatosis, has been identified as a key negative regulator for nuclear factor-{kappa}B (NF-{kappa}B) signaling, T cell development, B cell development, and tumor cell proliferation (15-21). Most recently we have shown that CYLD is induced by Gram-negative and Gram-positive bacterial pathogens and that CYLD regulates acute lung injury in lethal S. pneumoniae infections (16, 18, 22, 23). The biological role of CYLD in S. pneumoniae-induced inflammation, however, remains largely unknown.

In the present study, we investigated the molecular mechanisms underlying S. pneumoniae-induced NFAT activation and the subsequent inflammatory mediator production. We show that S. pneumoniae PLY activates NFAT transcription factor and subsequent inflammatory mediator production. S. pneumoniae-induced NFAT activation is mediated by Ca2+-calcineurin and transforming growth factor-β-activated kinase 1(TAK1)-mitogen-activated kinase kinase (MKK) 3/6-p38{alpha}/β pathways independently of Toll-like receptor 2 (TLR2) and TLR4. Moreover, we show that deubiquitinating enzyme CYLD inhibits S. pneumoniae-induced NFAT activation and subsequent inflammatory mediator production through negative cross-talk with TAK1. Our study thus provides new insights into a novel role of NFAT signaling pathway in S. pneumoniae-induced inflammation and also identifies CYLD as a critical negative regulator for NFAT signaling pathway.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents and Plasmids—Nifedipine was purchased from BIOMOL International (Plymouth Meeting, PA). SB203580 and ionomycin were purchased from Calbiochem (La Jolla, CA). Cyclosporin A (CsA) and EGTA were purchased from Sigma-Aldrich. The plasmids NFAT luciferase reporter, NF-{kappa}B luciferase reporter, p38{alpha}DN, p38βDN, MKK3DN, MKK6DN, TAK1DN, TAK1WT, siRNA-CYLD, wild-type CYLD (FLAG-tagged), deubiquitinase mutant CYLD-C/S, and CYLD-H/N were previously described (15, 16, 24, 25).

Bacterial Strains, Culture Conditions, and Purification of PLY—Clinical isolates of S. pneumoniae strains D39 (S.p.) and D39 isogenic PLY-deficient mutant (Ply mt) were used in this study. S. pneumoniae was grown on chocolate agar plates and in Todd-Hewitt broth supplemented with 0.5% yeast extract at 37 °C in a humidified 5% CO2 water-jacketed incubator. After overnight incubation, S. pneumoniae was centrifuged at 10,000 x g for 10 min, and the supernatant was discarded. The resulting pellet of S. pneumoniae was suspended in phosphate-buffered saline and sonicated. Subsequently, the lysates were collected and stored at -70 °C (27). The purification of PLY was performed as described previously (28).

Cell Culture—Human lung epithelial cell line A549 and human cervix epithelial cell line HeLa cells were maintained as described previously (22). Stable cell lines HEK293-pcDNA, HEK293-TLR2, and HEK293-TLR4 were kindly provided by Dr. Douglas T. Golenbock. All stable cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 0.5 mg/ml G418, and 10 µg/ml ciprofloxacin (Cellgro, Herndon, VA) as described (15). Wild-type (WT), Cyld-/-, Tlr2-/-, and Tlr4-/- mouse embryonic fibro-blasts (MEFs) were obtained from E13 embryos and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 units/ml, 0.1 mg/ml, respectively). WT, Cyld-/-, Tlr2-/-, and Tlr4-/- MEFs and mice were obtained as described previously (17, 23, 28). All cells were maintained at 37 °C in an atmosphere of 5% CO2.

Transfections and Luciferase Assay—Cells were cultured on 24-well plates. After 24 h, cells were co-transfected with NFAT or NF-{kappa}B luciferase reporter plasmid and various expression plasmids as indicated in the figures or figure legends. All transfections were carried out in triplicate using TransIT-LT1 reagent (Mirus, Madison, WI) following the manufacturer's instruction. In all co-transfections, an empty vector was used as a control. At 40 h after the transfection, cells were pretreated with or without chemical inhibitors, including EGTA, nifedipine, CsA, and SB203580 for 1 h. S. pneumoniae D39, Ply mt, PLY, or ionomycin were then added to the cells for 5 h before cell lysis for luciferase assay. Luciferase activity was normalized with respect to β-galactosidase activity.

Real-time Quantitative PCR Analysis—Total RNA was isolated with TRIzol reagent (Invitrogen) by following the manufacturer's instruction. For the reverse transcription reaction, TaqMan reverse transcription reagents (Applied Biosystems) were used as described (22). PCR amplifications were performed by using SYBR Green Universal Master Mix for human cyclo-oxygenase-2 (COX-2), IL-6, mouse COX-2, and mouse IL-6. In brief, reactions were performed in duplicate containing 2x Universal Master Mix, 1 µl of template cDNA, 100 nM primers in a final volume of 12.5 µl, and they were analyzed in a 96-well optical reaction plate (Applied Biosystems). Reactions were amplified and quantified by using an ABI 7500 sequence detector and the manufacturer's corresponding software (7000v1.3.1; Applied Biosystems). The relative quantities of mRNAs were obtained by using the comparative Ct method and were normalized with predeveloped Taqman assay reagent human cyclophilin or mouse glyceraldehydes-3-phosphate dehydrogenase as an endogenous control (Applied Biosystems). The primers for human COX-2 were as follows: forward primer, 5'-GAATCATTCACCAGGCAAATTG-3'; reverse primer, 5'-TCTGTACTGCGGGTGGAACA-3'. The primers for mouse COX-2 were as follows: forward primer, 5'-CCAGCACTTCACCCATCAGTT-3'; reverse primer, 5'-ACCCAGGTCCTCGCTTATGA-3'. The primers for human IL-6 were as follows: forward primer, 5'-GGTACATCCTCGACGGCATCT-3'; reverse primer, 5'-GTGCCTCTTTGCTGCTTTCAC-3'. The primers for mouse IL-6 were as follows: forward primer, 5'-GAGGATACCACTCCCAACAGACC-3'; reverse primer, 5'-AAGTGCATCATCGTTGTTCATACA-3'.

Western Blot Analysis and Immunoprecipitation—Antibodies against phospho-MKK3/6 (Ser-189/207), MKK3, phospho-p38 MAPK (Thr-180/Tyr-182), and p38 MAPK were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against CYLD were purchased from Imgenex Corp. (San Diego, CA). Antibodies against ubiquitin and TAK1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody against β-actin was purchased from Sigma. Western blot analysis was performed as described previously and following the manufacturer's instruction (22, 29). For immunoprecipitation, cells were lysed in lysis buffer (20 mM Tris base, 50 mM NaCl, 50 mM sodium pyrophosphate, 30 mM NaF, 5 µM zinc chloride, 2 mM iodoacetic acid, 1% Triton X-100, pH 7.4) supplemented with protease inhibitors. 500 µg of cell lysates were precleared with protein A/G-agarose beads (Santa Cruz Biotechnology) for 1 h at 4 °C. After centrifugation (3,000 x g, 2 min, 4 °C), supernatant was reacted with 2 µg of the appropriate antibodies overnight at 4 °C. After overnight incubation, protein A/G-agarose beads were added and then incubated for 2 h. Immunoprecipitates were washed four times with the lysis buffer and suspended in a sample buffer (15% glycerol, 0.14 M Tris-HCl, pH 6.8, 1.0% SDS, 0.5 M dithiothreitol, 0.0006% bromphenol blue).


Figure 1
View larger version (43K):
[in this window]
[in a new window]

  		FIGURE 1.
S. pneumoniae PLY activates NFAT-dependent inflammatory response in vitro and in vivo. A, S. pneumoniae (S.p.) induces NFAT promoter activity in a dose-dependent manner (7.5, 15, 30 µg/ml of S. pneumoniae lysate) in HEK293 cells. B, PLY-deficient mutant (Ply mt) did not induce NFAT promoter activity (15 µg/ml of both S. pneumoniae and Ply mt lysate, 60 ng/ml of purified PLY protein, left panel), whereas PLY induced NFAT promoter activity in a dose-dependent manner (30, 60, 90 ng/ml, right panel). C, DNA binding activity of NFAT was analyzed by EMSA. D, Q-PCR analysis of human COX-2 and IL-6 mRNA expression was carried out in human HEK293 and lung epithelial A549 cells treated with or without S. pneumoniae or PLY for 5 h. E, S. pneumoniae and PLY, but not Ply mt, induced COX-2 and IL-6 expression in C57BL/6 mice lungs in vivo. Six hours after intra-tracheal inoculation with S. pneumoniae, Ply mt, or PLY, lung RNA was isolated and Q-PCR analysis was performed. Values are the mean ± S.D. (n = 3 for A, B, D, and E). Data shown in C are representative of three independent experiments.

 
Nuclear Protein Extraction and Electrophoretic Mobility Shift Assay—Nuclear protein extraction was performed as described previously (30, 31). 5-7 µg of nuclear extracts was prepared and non-radioactive electrophoretic mobility shift assay was performed using an EMSA kit according to the manufacturer's instruction (Pierce). Oligonucleotide (oligo) 5'-ACGCCCAAAGAGGAAAATTTGTTTCATACA-3' was used as the consensus NFAT binding site-containing probe. Oligo was obtained from Integrated DNA Technologies and end-labeled with biotin-N4-CTP using terminal deoxynucleotidyl transferase (Pierce).

Calcineurin Phosphatase Assay—Calcineurin phosphatase activity was measured by using the Calcineurin Assay kit (BIOMOL) according to the manufacturer's instruction.

Animal and Animal Experiments—C57BL/6 strain was purchased from NCI, National Institutes of Health). Cyld-/- mice were reported previously (23). For S. pneumoniae- or PLY-induced inflammation in the lungs of the mice, under anesthesia animals were intratracheally inoculated with 5 x 107 colony-forming units of S. pneumoniae D39 or Ply mt lysate or 180 ng of PLY in 50 µl of saline; 50 µl of saline was inoculated as control inoculation in all the experiments. Animals were sacrificed 6 h after inoculation with an overdose injection of sodium pentobarbital, and mRNA expressions of COX-2 and IL-6 were measured from the lung tissues of inoculated mice by Q-PCR analysis as described above. For the S. pneumoniae-induced inflammation in Cyld-/- mice, both wild-type and Cyld-/- mice were intratracheally inoculated with 1 x 107 colony-forming units of S. pneumoniae, and mRNA expressions of COX-2 and IL-6 were measured from the lung tissues of wild-type and Cyld-/- mice 6 h after inoculation. Broncho-alveolar lavage (BAL) was performed as described previously to measure inflammatory cell migration into the airway from the lungs of wild-type and Cyld-/- mice, and cell number from the BAL fluid was counted under the microscope (18). All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Rochester.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
S. pneumoniae PLY Acts as a Potent Inducer of NFAT and the Subsequent Inflammatory Mediators in Vitro and in Vivo—To determine whether S. pneumoniae induces NFAT activation and NFAT-dependent inflammatory response, we first investigatedNFAT-dependent transcriptional activity by using NFAT-dependent luciferase reporter in HEK293 cells. As shown in Fig. 1A, S. pneumoniae (S.p.) induced NFAT activation in a dose-dependent manner, and similar results were observed in HeLa and A549 cells (data not shown). We have shown previously that PLY is an important virulence factor in S. pneumoniae infections (23, 28). To determine whether PLY plays an important role in S. pneumoniae-induced NFAT activation, NFAT promoter assay was performed using S. pneumoniae wild-type D39 and isogenic mutant Ply mt. As shown in Fig. 1B, NFAT promoter activation was induced by S. pneumoniae D39 and PLY, but not by PLY-deficient mutant Ply mt. Moreover, PLY induced NFAT activation in a dose-dependent manner. Consistent with these results, DNA binding activity of NFAT was markedly induced by S. pneumoniae (Fig. 1C). Because a variety of genes involved in inflammatory response undergo changes in expression pattern in response to bacterial infection, it is of particular interest and important to determine whether S. pneumoniae induces NFAT expression. We performed experiments to evaluate the effect of S. pneumoniae lysate on NFAT expressions. Lung epithelial cell A549 was first treated with S. pneumoniae lysate, and the expression of NFAT1, 2, 3, 4, and 5 at mRNA levels was then measured by performing real-time quantitative RT-PCR analysis. Interestingly, none of the NFAT isotypes was up-regulated by S. pneumoniae lysate (data not shown). This finding suggests that S. pneumoniae induces NFAT activity mainly by inducing its activation rather than up-regulating its expression (14).


Figure 2
View larger version (41K):
[in this window]
[in a new window]

  		FIGURE 2.
S. pneumoniae activates Ca2+-calcineurin-dependent NFAT signaling independently of TLR2 and TLR4 signaling. A, NFAT promoter activity was induced by S. pneumoniae in HEK293-pcDNA, HEK293-TLR2, and HEK293-TLR4 cells. B, NFAT promoter activity was induced by S. pneumoniae in wild-type MEF, Tlr2-/-, MEFs, and Tlr4-/- MEFs. C, S. pneumoniae-induced NFAT activation was inhibited by Ca2+ chelator EGTA (0.5 mM) but not by L-type Ca2+ channel blocker nifedipine (30 µM). D, S. pneumoniae-induced NFAT activation was inhibited by a specific calcineurin inhibitor, CsA, in a dose-dependent manner (1 µg/ml and 5 µg/ml). E, COX-2 mRNA induced by S. pneumoniae was inhibited by CsA in a dose-dependent manner (1 and 5 µg/ml) in HEK293 cells. F, calcineurin phosphatase activity was measured by using a calcineurin (CaN) assay kit. Ten minutes after S. pneumoniae treatment, protein was isolated for calcineurin assay analysis. Values are the mean ± S.D. (n = 3 for A-F) S.p., S. pneumoniae; Con, control.

 
To further determine whether S. pneumoniae also induces NFAT-dependent expression of inflammatory mediators, we investigated the effects of S. pneumoniae on expression of COX-2 and IL-6, which are known as NFAT-dependent genes (32, 33), by Q-PCR analysis. As shown in Fig. 1D, both COX-2 and IL-6 were markedly induced by S. pneumoniae and PLY in both HEK293 cells and lung epithelial cell line A549. To further determine whether S. pneumoniae also induces NFAT-dependent gene expression in vivo, we investigated the expression of COX-2 and IL-6 by Q-PCR analysis in the lungs of C57BL/6 mice. As shown in Fig. 1E, both COX-2 and IL-6 were up-regulated in the lungs of S. pneumoniae- or PLY-inoculated mice, but not in the lungs of Ply mt-inoculated mice. Collectively, these data demonstrate that S. pneumoniae PLY induces NFAT activation and the subsequent inflammatory mediators both in vitro and in vivo.

S. pneumoniae Activates NFAT Transcription Factor Independently of TLR2 or TLR4—Because of the important roles of Toll-like receptor (TLR) 2 and TLR4 in cellular responses to pneumococcal components (34-36), we investigated whether TLR2 or TLR4 is involved in activation of NFAT by S. pneumoniae by using a variety of HEK293 cells that stably overexpress either TLR2, TLR4, or an empty vector (HEK293-TLR2, HEK293-TLR4, and HEK293-pcDNA, respectively). Surprisingly, S. pneumoniae induced potent NFAT activation even in HEK293-pcDNA cells, which do not express TLR2 or TLR4 (Fig. 2A). These results are rather unexpected, because both TLR2 and TLR4 were previously shown to be important for the host defense response against S. pneumoniae infections. To further confirm the requirement of both TLR2 and/or TLR4 for S. pneumoniae-induced NFAT activation, we performed NFAT promoter assay in Tlr2-/- and Tlr4-/- MEFs. As shown in Fig. 2B, S. pneumoniae still induced potent NFAT activation in Tlr2-/- or Tlr4-/- MEFs. Taken together, we conclude from these data that TLR2 or TLR4 signaling pathway is not required for S. pneumoniae-induced NFAT activation.

S. pneumoniae Activates NFAT through Ca2+-calcineurin Signaling Pathway—Having demonstrated the role of PLY in inducing NFAT-dependent expression of inflammatory mediators, we next sought to investigate the signaling mechanisms underlying NFAT activation by PLY. Based on previous studies showing that PLY induces cellular Ca2+ influx in various cell types, and the important role of Ca2+ for NFAT signaling (10, 37, 38), we investigated the role of Ca2+ in S. pneumoniae-induced NFAT activation. As shown in Fig. 2C, a specific Ca2+ chelator, EGTA, greatly inhibited S. pneumoniae-induced NFAT activation. Because of the important role of the L-type Ca2+ channel for Ca2+ influx and NFAT activation (39), we next investigated the requirement of L-type Ca2+ channel by using its specific inhibitor, nifedipine. As shown in Fig. 2C, S. pneumoniae-induced NFAT activation was not inhibited by nifedipine. Collectively, these data demonstrate that S. pneumoniae induces NFAT activation via a PLY-induced Ca2+ influx, but not L-type Ca2+ channel.

NFAT is normally present in the cytoplasm in an inactive state and is highly phosphorylated. To translocate NFAT into the nucleus, NFAT needs to be dephosphorylated. A common phosphatase to achieve dephosphorylation of NFAT is calcineurin, a Ca2+/calmodulin-dependent serine-threonine phosphatase (10, 14). To determine the involvement of calcineurin in S. pneumoniae-induced NFAT activation, we investigated the effects of CsA, a specific inhibitor for calcineurin, on NFAT activation using NFAT reporter assay and Q-PCR analysis. As shown in Fig. 2, D and E, pretreatment with CsA inhibited S. pneumoniae-induced NFAT activation and COX-2 expression in a dose-dependent manner. Moreover, to investigate whether S. pneumoniae activates calcineurin phosphatase, we measured calcineurin phosphatase activity upon S. pneumoniae treatment. As shown in Fig. 2F, S. pneumoniae induced calcineurin activity. Taken together, our data indicate that S. pneumoniae activates NFAT-dependent gene expression through a Ca2+-calcineurin-dependent signaling pathway.


Figure 3
View larger version (47K):
[in this window]
[in a new window]

  		FIGURE 3.
S. pneumoniae activates NFAT signaling through TAK1-MKK3/6-p38{alpha}/β pathway. A, S. pneumoniae induced phosphorylation of MKK3/6 and p38 MAPK in HEK293 cells in a time-dependent manner as assessed by Western blot analysis. B, S. pneumoniae-induced NFAT activation was inhibited by SB203580 (SB), a specific inhibitor for p38 (20 µM), and by expressing p38{alpha} DN or p38β DN. C, S. pneumoniae-induced NFAT activation was inhibited by expressing MKK3 DN, MKK6 DN, and TAK1 DN. D, ionomycin induced phosphorylation of p38 MAPK in HEK293 cells in a time-dependent manner as assessed by Western blot analysis. E, ionomycin-induced NFAT activation was inhibited by SB (20 µM) and by expressing p38{alpha} DN or p38β DN. F, ionomycin-induced NFAT activation was inhibited by expressing MKK3 DN, MKK6 DN, and TAK1 DN. G, ionomycin-induced NFAT activation was inhibited by co-treatment with SB (5 µM) and CsA (1 µg/ml) to a greater extent. Values are the mean ± S.D. (n = 3 for B, C, E, and F). Data shown in A and D are representative of three independent experiments. S.p, S. pneumoniae; PBS, phosphate-buffered saline; Con, control.

 
S. pneumoniae Activates NFAT through Ca2+ Influx-TAK1-MKK3/6-p38{alpha}/β Pathway—Because we recently have demonstrated the important role of p38 MAPK in S. pneumoniae infections (23, 40), we investigated the involvement of MKK3/6-p38 MAPK pathway in S. pneumoniae-induced NFAT activation. We first examined whether S. pneumoniae induces activation of MKK3/6 and p38 MAPK. As shown in Fig. 3A, S. pneumoniae induced activation of MKK3/6 and p38 MAPK in epithelial cells. We next investigated the requirement of MKK3/6-p38 MAPK in NFAT activation. As shown in Fig. 3B, a specific inhibitor for p38 MAPK, SB203580 (SB), inhibited NFAT activation. We further confirmed its involvement by overexpressing the dominant negative (DN) mutant form of p38{alpha} or p38β. As expected, overexpression of both p38{alpha} DN and p38β DN inhibited NFAT activation. We next sought to determine which upstream molecules transduce signals to p38 MAPK in mediating NFAT activation. Among the numerous molecules, MKK3, MKK6, and TAK1 have been shown to play important roles in p38 MAPK activation (25). As shown in Fig. 3C, overexpressing MKK3 DN, MKK6 DN, and TAK1 DN inhibited NFAT activation by S. pneumoniae. Because of the important role of Ca2+ influx in S. pneumoniae-induced NFAT activation, we next investigated whether Ca2+ influx induces p38 MAPK activation. As shown in Fig. 3D, the Ca2+ ionophore ionomycin induced activation of p38 MAPK in HEK293 cells. We further investigated the requirement of p38 MAPK and its upstream signaling molecules, including MKK3/6 and TAK1. As shown in Fig. 3, E and F, SB treatment and overexpression of p38{alpha} DN, p38β DN, MKK3 DN, MKK6 DN, and TAK1 DN inhibited ionomycin-induced NFAT activation. Finally, we determined whether calcineurin and p38 MAPK are involved in NFAT activation as separate pathways. As shown in Fig. 3G, co-treatment with both SB and CsA inhibited S. pneumoniae-induced NFAT activation to a greater extent than with An SB or CsA alone. Collectively, these data demonstrate that Ca2+ influx-TAK1-MKK3/6-p38{alpha}/β signaling is required for NFAT activation by S. pneumoniae and that Ca2+-induced calcineurin and Ca2+-induced p38 signaling are involved in mediating S. pneumoniae-induced NFAT activation as separate pathways.

S. pneumoniae-induced NFAT Signaling Is Negatively Regulated by CYLD—Recently, the tumor suppressor CYLD, also known as a deubiquitinating enzyme, has been identified as a key negative regulator for NF-{kappa}B signaling (15, 26). The role of CYLD in regulating other key signaling pathways involved in mediating inflammation such as NFAT, however, remains largely unknown. Moreover, based on our recent study showing that CYLD is greatly induced by bacterial pathogens, including S. pneumoniae (16-18, 22, 23), we hypothesized that CYLD may play an important role in S. pneumoniae-induced NFAT activation. We first investigated whether CYLD regulates NFAT signaling in human epithelial cells by using siRNA and overexpression of WT CYLD. Interestingly, CYLD knock down by siRNA-CYLD potently enhanced S. pneumoniae-induced NFAT activation, whereas overexpression of WT CYLD inhibited (Fig. 4A). Likewise, expression of NFAT-regulated gene COX-2 was enhanced by siRNA-CYLD at the mRNA level, whereas overexpression of wild-type CYLD inhibited it (Fig. 4B). To further investigate the role of CYLD, we took advantage of available Cyld-/- MEFs. Consistent with the results obtained by using siRNA-CYLD, S. pneumoniae-induced NFAT activation was much greater in Cyld-/- MEFs than in Cyld+/+ MEFs (Fig. 4C). We next determined whether CYLD indeed acts as a negative regulator for S. pneumoniae-induced NFAT-dependent gene expression. Fig. 4D shows that S. pneumoniae induced COX-2 mRNA expression in Cyld-/- MEFs to a greater extent than in Cyld+/+ MEFs. Similar results were observed in S. pneumoniae-induced IL-6 mRNA expression. The in vivo relevance of these data were further confirmed by using the lungs of Cyld-/- mice. As shown in Fig. 4E, expression of both COX-2 and IL-6 was further enhanced in the lungs of Cyld-/- mice inoculated with S. pneumoniae compared with Cyld+/+ mice. Moreover, S. pneumoniae-induced inflammatory cell migration into the airway was also enhanced in Cyld-/- mice (Fig. 4F). Together, our data indicate that CYLD negatively regulates S. pneumoniae-induced NFAT activation and subsequent NFAT-regulated inflammatory mediators in vitro and in vivo.


Figure 4
View larger version (52K):
[in this window]
[in a new window]

  		FIGURE 4.
S. pneumoniae-induced NFAT signaling is negatively regulated by CYLD. A, S. pneumoniae-induced NFAT activation was enhanced by CYLD knock down using siRNA in HEK293 cells (left panel), whereas S. pneumoniae-induced NFAT activation was inhibited by wild-type CYLD overexpression (right panel). B, S. pneumoniae-induced COX-2 mRNA expression was enhanced by siRNA-CYLD (left panel), whereas S. pneumoniae-induced COX-2 mRNA expression was inhibited by wild-type CYLD overexpression (right panel). C, NFAT activation by S. pneumoniae is much greater in Cyld-/- MEF than Cyld+/+ MEF. D, S. pneumoniae induced COX-2 and IL-6 mRNA expression to a greater extent in Cyld-/- MEF than in Cyld+/+ MEF. E, both COX-2 and IL-6 mRNA expression was enhanced in Cyld-/- mouse lung compared with Cyld+/+ mouse lung inoculated with S. pneumoniae for 6 h. F, S. pneumoniae-induced inflammatory cell migration into airway was enhanced in Cyld-/- mice. Values are the mean ± S.D. (n = 3 for A-F). S.p., S. pneumoniae; Con, control.

 
CYLD Negatively Regulates S. pneumoniae-induced NFAT Signaling via Deubiquitination of TAK1—Having identified CYLD as a negative regulator for S. pneumoniae-induced NFAT signaling, we next sought to determine how CYLD negatively regulates NFAT signaling pathway. Because CYLD has been identified as a deubiquitinating enzyme, we investigated the requirement of CYLD deubiquitinating activity in NFAT signaling. As shown in Fig. 5A, deubiquitinase-deficient CYLD mutants (CYLD C/S and CYLD H/N) exhibited no inhibitory effect on S. pneumoniae-induced NFAT transcriptional activity, whereas NFAT activation was inhibited by overexpression of wild-type CYLD. Expression of COX-2 was also inhibited by overexpressing wild-type CYLD but not by deubiquitinase-deficient mutants (CYLD-C/S and CYLD-H/N) as assessed by Q-PCR analysis (Fig. 5B). Similar results were observed in Cyld-/- MEFs (data not shown). Thus, our data demonstrate that CYLD inhibits NFAT signaling pathway in a deubiquitinase activity-dependent manner. We next sought to determine the target molecule of CYLD. We first investigated whether CYLD inhibits S. pneumoniae-induced NFAT activation by targeting calcineurin. As shown in Fig. 5C, knock down of CYLD by siRNA exhibited no inhibitory effect on calcineurin activity. Because recent reports demonstrated that TAK1 polyubiquitination is involved in its activation and TAK1 interacts with and is deubiquitinated by CYLD to prevent the excessive activation of T cells (41, 42), we sought to determine whether CYLD acts as a negative regulator for S. pneumoniae-induced NFAT signaling through deubiquitinating TAK1. We first determined whether S. pneumoniae induces TAK1 polyubiquitination. As shown in Fig. 5D, S. pneumoniae induced TAK1 polyubiquitination in a time-dependent manner. We next evaluated whether overexpressing CYLD WT inhibits TAK1 polyubiquitination. As shown in Fig. 5E, the overexpression of CYLD WT inhibited S. pneumoniae-induced TAK1 polyubiquitination. Moreover, the interaction between CYLD and TAK1 was identified by performing co-immunoprecipitation experiments (Fig. 5F). Finally, to confirm whether CYLD also negatively regulates S. pneumoniae-induced MKK3/6-p38{alpha}/β pathway, Western blot analysis was performed. As shown in Fig. 5G, S. pneumoniae-induced phosphorylation of both MKK3/6 and p38{alpha}/β was enhanced in Cyld-/- MEFs compared with Cyld+/+ MEFs. Taken together, our data demonstrate that S. pneumoniae induces TAK1 polyubiquitination and CYLD interacts with TAK1 and deubiquitinates TAK1, thus acting as a negative regulator for S. pneumoniae-induced NFAT signaling and the subsequent induction of NFAT-dependent inflammatory mediators.


Figure 5
View larger version (61K):
[in this window]
[in a new window]

  		FIGURE 5.
S. pneumoniae-induced NFAT signaling is negatively regulated by CYLD via deubiquitination of TAK1. A, S. pneumoniae-induced NFAT activation was inhibited by overexpressing wild-type (WT) but not deubiquitinase-deficient mutants CYLD-C/S or CYLD-H/N in HEK293 cells. B, S. pneumoniae-induced COX-2 mRNA expression was inhibited by expressing wild-type, but not CYLD-C/S or CYLD-H/N. C, CYLD knock down by siRNA-CYLD exhibited no significant effect on S. pneumoniae-induced calcineurin (CaN) phosphatase activity. D, S. pneumoniae induced polyubiquitination of TAK1 in a time-dependent manner. E, co-expressing wild-type CYLD inhibited polyubiquitination of TAK1 in HEK293 cells. F, CYLD interacts with TAK1 protein in HEK293 cells as assessed by co-immunoprecipitation experiments. G, S. pneumoniae-induced MKK3/6-p38 MAPK activation was enhanced in Cyld-/- MEF compared with Cyld+/+ MEF. Values are the mean ± S.D. (n = 3 for A-C). Data shown in D-G are representative of three or more independent experiments. S.p., S. pneumoniae; Con, control.

 


Figure 6
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 6.
Schematic representation of the signaling mechanisms underlying negative regulation of S. pneumoniae-induced NFAT-dependent inflammation by CYLD.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we provide direct evidence that S. pneumoniae PLY activates NFAT transcription factor and induces subsequent up-regulation of inflammatory mediators such as COX-2 and IL-6 in vitro and in vivo. S. pneumoniae-induced NFAT activation is mediated by Ca2+-calcineurin pathway and TAK1-MKK3/6-p38{alpha}/β pathway independently of both TLR2 and TLR4. Interestingly, the deubiquitinating enzyme CYLD negatively regulates S. pneumoniae-induced NFAT signaling and subsequent expression of inflammatory mediators. We have also shown that CYLD interacts with and deubiquitinates TAK1 and in turn negatively regulates activation of its downstream signaling molecules, including MKK3/6 and p38{alpha}/β. These data thus reveal a novel role of CYLD in negatively regulating NFAT signaling pathway (Fig. 6).

An important finding in this study is the direct evidence that S. pneumoniae potently induces NFAT transcriptional activity and subsequent expression of inflammatory mediators. Our findings may have important implications for host defense and innate immune response to S. pneumoniae infections. Despite a number of studies demonstrating the involvement of S. pneumoniae PLY in NF-{kappa}B-dependent inflammation at relatively later stages of infections, the role of PLY in inducing NFAT-dependent inflammation remains totally unknown. In the present study, we provided evidence for the first time to demonstrate NFAT activation and the resultant induction of pro-inflammatory mediators by S. pneumoniae PLY. Previous study showed that S. pneumoniae induced delayed activation of NF-{kappa}Bin mouse lung compared with lipopolysaccharide (43). In line with this finding, our recent study demonstrates that NF-{kappa}B activation by S. pneumoniae PLY does not appear to play a crucial role in the pathogenesis of S. pneumoniae infections at the early stage (23). Thus, PLY-induced NFAT activation and the subsequent up-regulation of pro-inflammatory mediators, such as COX-2 and IL-6, may play a critical role in the pathogenesis of S. pneumoniae infections at a relatively early stage. This notion is further supported by our data showing that S. pneumoniae PLY induces NFAT activation independently of both TLR2 and TLR4. It is now known that lung epithelial cells express relatively low levels of certain TLRs under physiological conditions and these TLRs are up-regulated during the course of infections. Thus TLR2- and TLR4-independent activation of NFAT by S. pneumoniae PLY may play a crucial role in initiating host inflammatory/immune responses at early stages of infections when the pathogens first encounter the host surface epithelial cells.

Another interesting finding in our study is that PLY plays a key role in S. pneumoniae-induced NFAT activation via a TLR-independent mechanism. Although PLY induces NF-{kappa}B activation in a TLR4-dependent manner (34), TLR4 is not required for NFAT activation by PLY. Thus, a question that has yet to be answered is how S. pneumoniae PLY regulates NFAT activation. One possibility is that PLY induces Ca2+ influx into the cells through its pore-forming action (37, 38). PLY has been known as a direct inducer of Ca2+ influx into the cells. The resultant Ca2+ influx in turn leads to activation of Ca2+/calmodulin-calcineurin signaling and subsequent NFAT activation. Indeed, our data (Fig. 2C) showed S. pneumoniae-induced NFAT activation was inhibited by EGTA, a known Ca2+ chelator. Future studies will focus on elucidating how exactly Ca2+ influx is involved in PLY-dependent NFAT activation viaa TAK1-dependent manner.

Of particular interest in our study is that we showed for the first time that CYLD negatively regulates S. pneumoniae-induced NFAT activation. A growing body of evidence suggests that the deubiquitinating enzyme CYLD may act as not only a negative regulator for NF-{kappa}B but also a negative regulator for many other cell signaling events (44). The present study provides convincing evidence for the negative regulation of NFAT by CYLD, thereby providing novel insights into our understanding of how CYLD delicately and tightly regulates inflammation via negative cross-talk with multiple key inflammation regulatory pathways. Moreover, although we previously reported that CYLD negatively regulates MKK3-p38 MAPK signaling pathway, it is still unknown how CYLD negatively regulates MKK3-p38 MAPK pathway. In the present study, we identified TAK1 as the target of CYLD in inhibitions of MKK3-p38 MAPK pathway. Our finding is in line with recent reports that demonstrated that TAK1 polyubiquitination is involved in its activation and TAK1 interacts with and is deubiquitinated by CYLD to prevent the excessive activation of T cells (41, 42). In summary, the present study identifies CYLD as a negative regulator for NFAT by deubiquitinating TAK1 and provides novel and interesting insights into the molecular pathogenesis of S. pneumoniae infection.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants DC005843 and DC004562 (to J. D. L.) and P01 HL077789 and RO1 HL088400 (to C. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Recipient of American Heart Association Established Investigator Award 0740021 N. Back

2 To whom correspondence should be addressed: Box 672, University of Rochester Medical Center, 601 Elmwood Ave., Rochester NY, 14642. Tel.: 585-275-7195; Fax: 585-276-2231; E-mail: Jian-Dong_Li{at}URMC.Rochester.edu.

3 The abbreviations used are: PLY, pneumolysin; DN, dominant negative; MEF, mouse embryonic fibroblast; Q-PCR, quantitative PCR; siRNA, small interfering RNA; TLR, Toll-like receptor; CYLD, cylindromatosis; IL, interleukin; NFAT, nuclear factor of activated T cell; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; TAK, transforming growth factor-β-activated kinase; CsA, cyclosporin A; HEK, human embryonic kidney; COX, cyclo-oxygenase. Back


   ACKNOWLEDGMENTS
 
We thank Dr. D. T. Golenbock, Dr. J. Han, Dr. R. Malley, and Dr. D. Briles for kindly providing various reagents. We thank the members of the laboratory of Hirofumi Kai in the Graduate School of Pharmaceutical Sciences at Kumamoto University and the members of the laboratory of Jian-Dong Li at the University of Rochester for stimulating scientific discussion.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Krutzik, S. R., Sieling, P. A., and Moslin, R. L. (2001) Curr. Opin. Immunol. 13, 104-108[CrossRef][Medline] [Order article via Infotrieve]
  2. Medzhitov, R., and Janeway, C., Jr. (2000) Trends Microbiol. 8, 452-456[CrossRef][Medline] [Order article via Infotrieve]
  3. Klugman, K. P., and Feldman, C. (2001) Curr. Opin. Infect. Dis. 14, 173-179[CrossRef][Medline] [Order article via Infotrieve]
  4. Berry, A. M., Yother, J., Briles, D. E., Hansman, D., and Paton, J. C. (1989) Infect. Immun. 57, 2037-2042[Abstract/Free Full Text]
  5. Benton, K. A., Everson, M. P., and Briles, D. E. (1995) Infect. Immun. 63, 448-455[Abstract]
  6. Wheeler, J., Freeman, R., Steward, M., Henderson, K., Lee, M. J., Piggott, N. H., Eltringham, G. F., and Galloway, A. (1999) J. Med. Microbiol. 48, 863-866[Abstract/Free Full Text]
  7. Gilbert, R. J., Jimernez, J. L., Chen, S., Tickle, I. J., Rossjohm, J., Parker, M., Andrew, P. W., and Saibil, H. R. (1999) Cell 97, 647-655[CrossRef][Medline] [Order article via Infotrieve]
  8. Arnold, K. E., Leggiadro, R. J., Breiman, R. F., Lipman, H. B., Schwartz, B., Appleton, M. A., Cleveland, K. O., Szeto, H. C., Hill, B. C., Tenover, F. C., Elliott, J. A., and Facklam, R. R. (1996) J. Pediatr. 128, 757-764[CrossRef][Medline] [Order article via Infotrieve]
  9. Duchin, J. S., Breiman, R. F., Diamond, A., Lipman, H. B., Block, S. L., Hedrick, J. A., Finger, R., and Elliot, J. A. (1995) Pediatr. Infect. Dis. J. 14, 745-750[Medline] [Order article via Infotrieve]
  10. Rao, A., Luo, C., and Hogan P. G. (1997) Annu. Rev. Immunol. 15, 707-747[CrossRef][Medline] [Order article via Infotrieve]
  11. Xia, Y., Wen, H. Y., and Kellems, R. E. (2002) J. Biol. Chem. 277, 24601-24608[Abstract/Free Full Text]
  12. Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima, K., and Takayanagi, H. (2005) Nat. Med. 11, 880-885[CrossRef][Medline] [Order article via Infotrieve]
  13. Kuwahara, K., Wang, Y., McAnally, J., Richardson, J. A., Bassel-Duby, R., Hill, J. A., and Olson, E. N. (2006) J. Clin. Investig. 116, 3114-3126[CrossRef][Medline] [Order article via Infotrieve]
  14. Macian, F. (2005) Nat. Rev. Immunol. 5, 472-484[CrossRef][Medline] [Order article via Infotrieve]
  15. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., and Mosialos, G. (2003) Nature 424, 793-796[CrossRef][Medline] [Order article via Infotrieve]
  16. Jono, H., Lim, J. H., Chen, L. F., Xu, H., Trompouki, E., Pan, Z. K., Mosialos, G., and Li, J. D. (2004) J. Biol. Chem. 279, 36171-36174[Abstract/Free Full Text]
  17. Sakai, A., Koga, T., Lim, J. H., Jono, H., Harada, K., Szymanski, E., Xu, H., Kai, H., and Li, J. D. (2007) FEBS J. 274, 3655-3668[CrossRef][Medline] [Order article via Infotrieve]
  18. Lim, J. H., Jono, H., Koga, T., Woo, C. H., Ishinaga, H., Bourne, P., Xu, H., Ha, U. H., Xu, H., and Li, J. D. (2007) PLoS ONE 2, e1032[CrossRef]
  19. Reiley, W. W., Zhang, M., Jin, W., Losiewicz, M., Donohue, K. B., Norbury, C. C., and Sun, S. C. (2006) Nat. Immunol. 7, 411-417[CrossRef][Medline] [Order article via Infotrieve]
  20. Jin, W., Reiley, W. R., Lee, A. J., Wright, A., Wu, X., Zhang, M., and Sun, S. C. (2007) J. Biol. Chem. 282, 15884-15893[Abstract/Free Full Text]
  21. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., and Fassler, R. (2006) Cell 125, 665-677[CrossRef][Medline] [Order article via Infotrieve]
  22. Yoshida, H., Jono, H., Kai, H., and Li, J. D. (2005) J. Biol. Chem. 280, 41111-41121[Abstract/Free Full Text]
  23. Lim, J. H., Stirling, B., Derry, J., Koga, T., Jono, H., Woo, C. H., Xu, H., Bourne, P., Ha, U. H., Ishinaga, H., Xu, H., Andalibi, A., Feng, X. H., Zhu, H., Huang, Y., Zhang, W., Weng, X., Yan, C., Yin, Z., Briles, D. E., Davis, R. J., Flavell, R. A., and Li, J. D. (2007) Immunity 27, 349-360[CrossRef][Medline] [Order article via Infotrieve]
  24. Shapiro, V. S., Mollenauer, M. N., Greene, W. C., and Weiss, A. (1996) J. Exp. Med. 184, 1663-1669[Abstract/Free Full Text]
  25. Shuto, T., Xu, H., Wang, B., Han, J., Kai, H., Gu, X. X., Murphy, T. F., Lim, D. J., and Li, J. D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8774-8779[Abstract/Free Full Text]
  26. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., and Courtois, G. (2003) Nature 424, 801-805[CrossRef][Medline] [Order article via Infotrieve]
  27. Kweon, S. M., Wang, B., Rixter, D., Lim, J. H., Koga, T., Ishinaga, H., Chen, L. F., Jono, H., Xu, H., and Li, J. D. (2006) Biochem. Biophys. Res. Commun. 351, 368-375[CrossRef][Medline] [Order article via Infotrieve]
  28. Ha, U., Lim, J. H., Jono, H., Koga, T., Srivastava, A., Malley, R., Pages, G., Pouyssegur, J., and Li, J. D. (2007) J. Immunol. 178, 1736-1747[Abstract/Free Full Text]
  29. Koga, T., Harada, H., Shi, T. S., Okada, S., Suico, M. A., Shuto, T., and Kai, H. (2005) Biochem. Biophys. Res. Commun. 337, 1319-1323[CrossRef][Medline] [Order article via Infotrieve]
  30. Ishinaga, H., Jono, H., Lim, J. H., Kweon, S. M., Xu, H., Ha, U. H., Xu, H., Koga, T., Yan, C., Feng, X. H., Chen, L. F., and Li, J. D. (2007) EMBO J. 26, 1150-1162[CrossRef][Medline] [Order article via Infotrieve]
  31. Koga, T., Suico, M. A., Nakamura, H., Taura, M., Lu, Z., Shuto, T., Okiyoneda, T., and Kai, H. (2005) FEBS Lett. 579, 2811-2816[CrossRef][Medline] [Order article via Infotrieve]
  32. Ding, J., Li, J., Xue, C., Wu, K., Ouyang, W., Zhang, D., Yan, Y., and Huang, C. (2006) J. Biol. Chem. 281, 24405-24413[Abstract/Free Full Text]
  33. Liu, Z., Dronadula, N., and Rao, G. N. (2004) J. Biol. Chem. 279, 41218-41226[Abstract/Free Full Text]
  34. Malley, R., Henneke, P., Morse, S. C., Cieslewicz, M. J., Lipsitch, M., Thompson, C. M., Kurt-Jones, E., Paton, J. C., Wessels, M. R., and Golenbock, D. T. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 1966-1971[Abstract/Free Full Text]
  35. van Rossum, A. M., Lysenko, E. S., and Weiser, J. N. (2005) Infect. Immun. 73, 7718-7726[Abstract/Free Full Text]
  36. Schmeck, B., Huber, S., Moog, K., Zahlten, J., Hocke, A. C., Opitz, B., Hammerschmidt, S., Mitchell, T. J., Kracht, M., Rosseau, S., Suttorp, N., and Hippenstiel, S. (2006) Am. J. Physiol. 290, L730-L737
  37. Iliev, A. I., Djannatian, J. R., Nau, R., Mitchell, T. J., and Wouters, F. S. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 2897-2902[Abstract/Free Full Text]
  38. Braun, J. S., Sbulett, J. E., Freyer, D., Mitchell, T. J., Cleveland, J. L., Tuomanen, E. I., and Weber, J. R. (2002) J. Clin. Investig. 109, 19-27[CrossRef][Medline] [Order article via Infotrieve]
  39. Onohara, N., Nishida, M., Inoue, R., Kobayashi, H., Sumimoto, H., Sato, Y., Mori, Y., Nagao, T., and Kurose, H. (2006) EMBO J. 25, 5305-5316[CrossRef][Medline] [Order article via Infotrieve]
  40. Ratner, A. J., Hippe, K. R., Aguilar, J. L., Bender, M. H., Nelson, A. L., and Weiser, J. N. (2006) J. Biol. Chem. 281, 12994-12998[Abstract/Free Full Text]
  41. Adhikari, A., Xu, M., and Chen, Z. J. (2007) Oncogene 26, 3214-3226[CrossRef][Medline] [Order article via Infotrieve]
  42. Reiley, W. W., Jin, W., Lee, A. J., Wright, A., Wu, X., Tewalt, E. F., Leonard, T. O., Fitzpatrick, L., Zhang, M., and Sun, S. C. (2007) J. Exp. Med. 204, 1475-1485[Abstract/Free Full Text]
  43. Amory-Rivier, C. F., Mohler, J., Bedos, J. P., Azoulay-Dupuis, E., Henin, D., Muffat-Joly, M., Carbon, C., and Moine, P. (2000) Crit. Care Med. 28, 3249-3256[CrossRef][Medline] [Order article via Infotrieve]
  44. Courtois, G. (2008) Cell Mol Life Sci. DOI: 10.1007/s00018-007-7465-4

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/18/12546    most recent
M710518200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koga, T.
Right arrow Articles by Li, J.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koga, T.
Right arrow Articles by Li, J.-D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement